NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
16729-0223-61 | 16729-0223 | temsirolimus | Temsirolimus | Chemotherapy | Enzyme Inhibitor | mTOR | Intravenous | Aug 13, 2018 | In Use | ||
73116-0115-02 | 73116-0115 | duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
00173-0846-08 | 00173-0846 | Dabrafenib | Tafinlar | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Jun 10, 2013 | Aug 31, 2018 | No Longer Used |
00078-0715-02 | 00078-0715 | Alpelisib | PIQRAY | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | ||
72237-0101-01 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
00093-7769-24 | 00093-7769 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 23, 2023 | In Use | |
70377-0011-23 | 70377-0011 | Everolimus | EVEROLIMUS | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 17, 2024 | In Use | |
00054-0480-14 | 00054-0480 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2020 | In Use | |
50881-0005-60 | 50881-0005 | Ruxolitinib | Jakafi | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Nov 16, 2011 | In Use | |
71779-0125-02 | 71779-0125 | duvelisib | Copiktra | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
00173-0847-65 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Oct 8, 2014 | May 31, 2018 | No Longer Used |
00078-1154-21 | 00078-1154 | Dabrafenib | Tafinlar | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Mar 16, 2023 | In Use | |
50881-0010-01 | 50881-0010 | Ruxolitinib | Jakafi | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1 and JAK 2 (Janus Kinase Inhibitor) | Oral | Nov 16, 2011 | In Use | |
69660-0202-91 | 69660-0202 | Rucaparib | Rubraca | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | May 1, 2017 | Jul 31, 2025 | In Use |
72611-0785-02 | 72611-0785 | Temsirolimus Injection | Temsirolimus | Chemotherapy | Enzyme Inhibitor | mTOR | Intravenous | May 8, 2020 | In Use | ||
00074-0561-14 | 00074-0561 | Venetoclax | Venclexta | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Apr 11, 2016 | In Use | |
00078-0701-84 | 00078-0701 | Alpelisib | PIQRAY | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
59572-0705-30 | 59572-0705 | Enasidenib mesylate | Idhifa | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH2 | Oral | Aug 1, 2017 | In Use | |
46014-0296-01 | 46014-0296 | talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct 26, 2018 | In Use | |
49884-0127-91 | 49884-0127 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Dec 10, 2019 | In Use | |
71332-0006-90 | 71332-0006 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jun 24, 2024 | In Use | |
00703-4004-01 | 00703-4004 | Romidepsin | Romidepsin | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Apr 14, 2020 | In Use | |
00074-0576-11 | 00074-0576 | Venetoclax | Venclexta | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Apr 11, 2016 | In Use | |
70377-0012-11 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
51991-0821-28 | 51991-0821 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use |
Found 11465 results — Export these results